, Nov. 5, 2010
/PRNewswire/ -- Shrink Nanotechnologies, Inc. ("Shrink") (OTC Bulletin Board: INKN), an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, revealed working videos of its first product offering the StemDisc450, a high-yield, low cost, patent-pending cell culturing biomedical research tool. Shrink expects to begin offering this product for sale in the first quarter of 2011 or sooner.
"Tissue engineering and cell culturing are high growth areas of the biotechnology field. This trend is being fueled as the idea of "personalized medicine" or "therapeutics and treatments made for you" - becomes a reality. And as the personalized medicine movement grows, biotech and pharmaceutical companies are focusing on the promise of novel research, especially new cellular-based therapies, to help combat cancer, spinal cord injuries, diabetes, Parkinson's and Alzheimer's disease, and many more. StemDisc is a platform for Shrink to offer a growing suite of products that will address an important spectrum of the needs within cellular and tissue engineering technologies and tools," statedMark L. Baum, CEO of Shrink Nanotechnologies, Inc.
"We are pleased to reveal a working StemDisc450 prototype, a device actually developing HESCs (human embryonic stem cells)," added Baum. "Shrink is exploring opportunities with established stem cell R&D companies for potential strategic partnerships for the sale and marketing of StemDisc products. Our primary target market is the more than 3,000 stem cell research labs and 15,000 biomedical laboratories operating in the United States."
The videos are available by following this link:
StemDisc is designed to improve embryoid body (EB) formation of stem cells at a higher rate and efficiency over current EB formation methods. The platform can be used to grow and differentiate human and animal single cells, human embryonic stem cells (HESCs) and induced pluri-potent stem cells (IPSCs). Versions of StemDisc's unique honeycomb-like well will be offered in different diameter and depth depending on the type of cell and application. Each round bottom "microwell" is capable of making 800 to 1,000 EBs, increasing the flexibility of use for researchers to achieve optimum EB formation with high reliability compared to legacy methods. A unique feature of the StemDisc product line is the optical transparency of the surface that the cells rest in. The StemDisc polymer offers amazing transparency, providing the cell biologist with the ability to see more of what she is doing as she completes her research. StemDisc's five micron walls between microwells virtually assure a clean transfer of the biological material into a well in a few easy steps, helping to further lower costs and accelerate the time to publish results of potentially life-saving studies. If you are interested in receiving more information about StemDisc, please contact us by visiting www.shrinknano.com.
About Shrink Nanotechnologies, Inc.
Shrink Nanotechnologies, Inc. is a one-of-a-kind FIGA organization, which focuses on leveraging contributions from experts in Finance, Industry, Government and Academia. Operating as a high-technology development-stage company, Shrink owns and develops proprietary and patent-pending nano-sized technologies, components and product systems. The Company's unique NanoShrink material is a pre-stressed polymer which is used in a patent pending manufacturing platform with numerous applications in the solar energy, human and animal diagnostics, and biotechnology research and development tools industries. For more information, please visit www.shrinknano.com.
For Shrink Nanotechnologies
Mark L. Baum, Esq.
Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only. Actual results may differ materially from those anticipated in this press release. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Shrink's ability to obtain additional financing and to build and develop markets for Shrink's biotechnology technologies and products. These factors should be strongly considered when making a decision to acquire or maintain a financial interest in Shrink, including consulting with a FINRA registered representative prior to making such decision. Shrink undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Shrink's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Shrink's success are more fully disclosed in Shrink's most recent public filings with the U.S. Securities and Exchange Commission.
SOURCE Shrink Nanotechnologies, Inc.